Clinical trial
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
NCT02419378 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
- Lead sponsor
- University Hospital Muenster
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2015
- Completion date
- November 30, 2020
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.